Private Equity 3 Hours

Last updated: June 4, 2026, 5:30 AM ET

European Deal Activity Highlighting bio:cap’s network role shows the firm stitching together research labs, hospitals and venture funds across the continent, a move that could accelerate cross‑border clinical trials and attract fresh capital into fragmented life‑science assets. At the same time, citing KPMG’s five‑plus‑five framework Tilman Ost warned that AI‑driven software buyouts will face “heightened scrutiny” in Europe, urging investors to target niche, mission‑critical applications where technology demonstrably improves margins. The combined focus on sector‑specific integration and tighter due‑diligence standards signals a sharpening of private‑equity strategy amid rapid tech adoption.